drugset
drugset / Trial / NCT02187107

A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials

NCT02187107 ↗

Phase 2 Completed 52 enrolled Tibotec Pharmaceuticals, Ireland
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was primarily to assess the long-term safety and tolerability of TMC114/rtv in addition to an individually optimized background antiretroviral therapy in HIV-1 infected participants. In addition, antiviral activity and immunological effect were also evaluated.

Timeline

Start
2005-01
Primary completion
2005-09
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Darunavir Small molecule 600 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral

Indications

HIV infectious disease